Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
Eagle Pharmaceuticals Inc (EGRX) の株価収益率はいくらですか?
Eagle Pharmaceuticals Inc の株価収益率は 0.5472 です。
EGRX の株価パフォーマンスは?
EGRX の現在の価格は $1 で、最終取引日から 0% decreased 変動しました。
Eagle Pharmaceuticals Inc の主な事業テーマや業界は?
Eagle Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。